Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

Benzinga · 4d ago
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.